sidebar - If results from previous trials continue somewhat the same a Lipitor warning would not be needed. They didn't show bad interaction with Atorvastastin , just didn't work nearly as well as with Rosuvastatin. In this case, Apabetalone would go to market as a Apabetalone/Rosuvastatin combo so a second statin would not be prescribed at the same time.